Sarepta Therapeutics

FDA
Favicon Fierce Pharma

Vinay Prasad is back at the FDA after last month's surprise ouster

“At the FDA’s request,” Vinay Prasad, M.D., is returning to lead CBER, an HHS spokesperson told Fierce Pharma.
Angus Liu Aug 9, 2025 12:22pm
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Jul 31, 2025 9:10am
FDA
Favicon Fierce Pharma

Vinay Prasad departs FDA amid controversy over gene therapy

Jul 30, 2025 9:33am
sarepta building
Favicon Fierce Pharma

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm
timer sand clocks time

Arrowhead meets $100M milestone, awaits Sarepta payment

Jul 28, 2025 3:10pm
FDA
Favicon Fierce Pharma

FDA eyeing study requirements to confirm Elevidys safety: report

Jul 24, 2025 3:12pm